Angelini Pharma and JCR Pharmaceuticals partner to develop new epilepsy therapies
Angelini Pharma and JCR Pharmaceuticals have announced that they have entered into an exclusive global development and commercialisation agreement for the development of novel therapies to treat epilepsy.
Angelini brings neurological disease expertise, while JCR provides scientific and technological knowledge, both with the aim of delivering biotherapeutics across the blood-brain barrier.
The companies will collaboratively lead the discovery and pre-clinical development for the identification of brain-penetrating biologic therapeutics while using JCR’s proprietary blood-brain barrier technology, J-Brain Cargo. Then, Angelini will have an exclusive license option to advance the therapeutic candidates as part of the collaboration into clinical development and global commercialisation, excluding Japan.
Jacaoi Andreose, CEO at Angelini Pharma, commented: “Epilepsy is one of the most prevalent chronic neurological diseases. In the past decade, it has been recognised as a social disease with high level of disability and mortality burden, and more research is urgently needed to identify targeted solutions for this underserved patient community. Through this strategic collaboration with JCR, a company with a wealth of biotechnological expertise, we will combine our respective strengths to explore the use of biologics in this area and accelerate critically needed treatment options for people living with epilepsy.”
Shin Ashida, chairman and president at JCR, added: ““The blood-brain-barrier has remained an elusive target in clinical research for neurological disease, and we are excited to partner with Angelini Pharma to bring forward new therapies for these patients. I believe that our proprietary J-Brain Cargo technology is an important key [in the] treatment of central nervous system disorders. Combining our key technologies with Angelini Pharma’s deep therapeutic knowledge in neurological diseases will create new treatment options for people living with epilepsy.”
The MHRA has granted marketing authorisation (MA) for Ontozry (cenobamate) for the treatment of focal-onset …
Accure Therapeutics, an R&D pharmaceutical company in the central nervous system (CNS) field, has announced …